CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00867 CMS

Market Closed 07-24 16:08:05

12.090

-0.230

-1.87%

High12.460	Low12.000	Vol4.00M
Open12.310	D1 Closing12.320	Amplitude3.73%
Mkt Cap29.41B	Tradable Cap29.41B	Total Shares2.43B
T/O48.34M	T/O Rate0.16%	Tradable Shares2.43B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"CMS","latestPrice":12.09,"timestamp":1784880485002,"preClose":12.32,"halted":0,"volume":3999000,"delay":0,"changeRate":-0.018668831168831203,"floatShares":2433000000,"shares":2433000000,"eps":0.6154,"marketStatus":"Market Closed","change":-0.23,"latestTime":"07-24 16:08:05","open":12.31,"high":12.46,"low":12,"amount":48344110,"amplitude":0.037338,"askPrice":12.09,"askSize":137000,"bidPrice":12.08,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":0.684786,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":7,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":12.32,"dividendRate":0.027802,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.625982137642164,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"2652576256","title":"Samsara Stock And 2 Founder Led Software Picks With Real Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2652576256","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652576256?lang=en_us&edition=fundamental","pubTime":"2026-07-19 11:34","pubTimestamp":1784432079,"startTime":"0","endTime":"0","summary":"Founder led companies can offer something many investors value in a world of shifting inflation data, mixed growth signals, and frequent policy surprises: leaders whose own reputations and long term vision are closely tied to shareholder outcomes. With global rates, energy costs, and consumer demand all pulling markets in different directions, backing founders who remain deeply invested in their business can be one way to focus on execution rather than headlines. This article highlights 3...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-iot/samsara/news/samsara-stock-and-2-founder-led-software-picks-with-real-rev","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-iot/samsara/news/samsara-stock-and-2-founder-led-software-picks-with-real-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00867","BK4613","IE00BMCWC346.EUR","SG9999015986.USD","BK4539","IE00BVYPNP33.GBP","PSIL","BK4588","IE00BYV24P56.USD","IE00BGHQDM52.EUR","BK1593","SG9999015952.SGD","SG9999004220.SGD","IOT","IOT.AU","BK1191","GHRS","IE00BVYPNQ40.USD","BK4023","LU2488822045.USD","BK4007","SG9999015978.USD","BK4585","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652328229","title":"On Holding Stock And 2 Founder Led Picks Investors Are Watching Closely","url":"https://stock-news.laohu8.com/highlight/detail?id=2652328229","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652328229?lang=en_us&edition=fundamental","pubTime":"2026-07-17 23:28","pubTimestamp":1784302133,"startTime":"0","endTime":"0","summary":"Founder led companies can be especially interesting when inflation, rates, energy costs, and growth momentum are all pulling markets in different directions. With central banks weighing inflation data, bond markets reacting to policy expectations, and sectors responding differently to trade, energy, and housing trends, many investors are looking for leaders who are deeply aligned with long term outcomes. This article focuses on that theme by using a founder led screener built around personal...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4121000-choice1-main-header/1585186790255","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4121000-choice1-main-header/1585186790255"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/on-holding-stock-and-2-founder-led-picks-investors-are-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/on-holding-stock-and-2-founder-led-picks-investors-are-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0289961442.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","LU0057025933.USD","ONON","00867","GHRS","IE00BMCWC346.EUR","LU0511384066.AUD","PSIL","IE00BVYPNQ40.USD","BK4007","SG9999015952.SGD","LU0289739343.SGD","BK1191","BK4585","BK4146","BK4588","LU2488822045.USD","BK4547","SG9999015986.USD","LU0069063385.USD","ISBC","BK4539","LU2265009873.SGD","BK1593","SG9999004220.SGD","LU1804176565.USD","IE00BYV24P56.USD","IE00BVYPNP33.GBP","LU0472753341.HKD","BK4211","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651418586","title":"China Medical System Secures Clinical Trial Approval for Macular Degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2651418586","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651418586?lang=en_us&edition=fundamental","pubTime":"2026-07-16 11:34","pubTimestamp":1784172853,"startTime":"0","endTime":"0","summary":"China Medical System  obtained approval from China's National Medical Products Administration for the clinical trial of the self-developed complement factor B inhibitor CMS-D017 capsules, according to a Wednesday filing with the Singapore Exchange.Under the approval, the pharmaceutical company can now conduct trials to evaluate the drug's safety and efficacy for treating age-related macular degeneration.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","SG9999015978.USD","SG9999004220.SGD","SG9999015986.USD","BK1191","BK1593","IE00BMCWC346.EUR","BK6079","00867","SG9999015952.SGD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","IE00BYV24P56.USD","SG9999015945.SGD","8A8.SI","IE00BVYPNQ40.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651185460","title":"China Medical System Says Nmpa Approves Clinical Trials of Cms-d017","url":"https://stock-news.laohu8.com/highlight/detail?id=2651185460","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651185460?lang=en_us&edition=fundamental","pubTime":"2026-07-16 01:45","pubTimestamp":1784137533,"startTime":"0","endTime":"0","summary":"BRIEF-China Medical System Says Nmpa Approves Clinical Trials Of CMS-D017July 15 (Reuters)-China Medical System Holdings Ltd0867.HK:NMPA APPROVES CLINICAL TRIALS OF CMS-D017 FOR AGE-RELATED MACULAR DEGENERATIONFurther company coverage:0867.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H050:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","IE00BYV24P56.USD","BK1191","SG9999015952.SGD","SG9999015986.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","00867","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","LU2488822045.USD","BK1593","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120825611","title":"CMS Receives Clinical Trial Approval for Its Novel Complement Factor B Inhibitor in Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=1120825611","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120825611?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:42","pubTimestamp":1784112170,"startTime":"0","endTime":"0","summary":"CMS (HKG: 00867) has announced that on July 15, 2026, its self-developed innovative drug, the complement factor B inhibitor CMS-D017 capsule, received a drug clinical trial approval notice from...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","LU0738911758.USD","LU1894683348.USD","SG9999015978.USD","159992","BMED","BK1593","SG9999015986.USD","IE00BYV24P56.USD","BK1161","LU0661504455.SGD","BK4585","LU0545039389.USD","BK1574","SG9999015945.SGD","CMS","00867","BK4208","LU0949170772.SGD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","MEDX","SG9999004220.SGD","BK1191","LU1003077747.HKD","IE00BMCWC346.EUR","BK4588","LU2637428348.USD","06978","LU2500361329.USD","SG9999015952.SGD","LU2346227817.USD","LU2488822045.USD","LU1894683264.USD","IE00BVYPNQ40.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139262068","title":"CMS secures NMPA clearance to begin clinical trials of oral complement factor B inhibitor CMS-D017 for age-related macular degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=1139262068","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139262068?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:41","pubTimestamp":1784112094,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited (CMS) announced on 15 July 2026 that the National Medical Products Administration has issued a Drug Clinical Trial Approval Notice authorising Phase I–III...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452306","title":"China Medical System Wins Trial Nod for New AMD Drug CMS-D017","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651452306?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:37","pubTimestamp":1784111834,"startTime":"0","endTime":"0","summary":"China Medical System Holdings ( ($HK:0867) ) just unveiled an announcement. China Medical System Holdings has obtained approval from China’s Nation...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/china-medical-system-wins-trial-nod-for-new-amd-drug-cms-d017?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/china-medical-system-wins-trial-nod-for-new-amd-drug-cms-d017?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","BK1593","SG9999015978.USD","SG9999015986.USD","IE00BYV24P56.USD","IE00BMCWC346.EUR","LU2488822045.USD","SG9999004220.SGD","SG9999015945.SGD","SG9999015952.SGD","IE00BVYPNQ40.USD","BK1191","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651245470","title":"China Medical System Holdings - Nmpa Approves Clinical Trials of Cms-d017 for Age-related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2651245470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651245470?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:34","pubTimestamp":1784111689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H050:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","00867","SG9999015978.USD","IE00BVYPNP33.GBP","BK1191","LU2488822045.USD","SG9999015952.SGD","IE00BYV24P56.USD","SG9999015986.USD","IE00BMCWC346.EUR","SG9999004220.SGD","BK1593","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156997423","title":"Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS","url":"https://stock-news.laohu8.com/highlight/detail?id=1156997423","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156997423?lang=en_us&edition=fundamental","pubTime":"2026-07-13 10:10","pubTimestamp":1783908642,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million. On July 13th, according to a post on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","IE00BYV24P56.USD","LFSC","ARTY","BK1191","QTOC","BBP","SBIO","CHAT","LU2488822045.USD","IE00BMCWC346.EUR","SG9999015952.SGD","BK4588","AGIX","SG9999015945.SGD","00867","AIPO","IE00BVYPNP33.GBP","IBB","PBE","SG9999015986.USD","BK1593","WRND","VTHR","GDOC","IE00BGHQDM52.EUR","SG9999004220.SGD","BK4585","SG9999015978.USD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162910","title":"China Medical System to Pay Insilico up to About $177 Million for Central Nervous System Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162910","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651162910?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:53","pubTimestamp":1783907601,"startTime":"0","endTime":"0","summary":"China Medical System to pay Insilico up to about $177 million for central nervous system workSHANGHAI, July 13 -Chinese drugmaker China Medical System0867.HKwill pay Insilico Medicine03696.HKup to about 1.2 billion yuan  in payments linked to milestones for work on a research and development programme in the central nervous system disease field, the Boston-based drug discovery firm said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUAC7RTHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQDM52.EUR","IE00BMCWC346.EUR","IE00BYV24P56.USD","03696","SG9999015945.SGD","SG9999015986.USD","SG9999004220.SGD","00867","IE00BVYPNP33.GBP","LU2488822045.USD","BK1141","BK1593","BK1191","SG9999015978.USD","SG9999015952.SGD","IE00BVYPNQ40.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651646481","title":"InSilico Medicine, CMS Expand Drug Development Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2651646481","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651646481?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:02","pubTimestamp":1783904540,"startTime":"0","endTime":"0","summary":"InSilico Medicine  expanded its collaboration with China Medical System  to jointly develop innovative drugs for central nervous system diseases, according to a Monday filing with the Hong Kong bourse.Under the agreement, InSilico will combine its artificial intelligence drug discovery platform with CMS' research and development capabilities and therapeutic expertise to advance the programs.InSilico said it is eligible to receive milestone payments of up to 1.20 billion yuan, plus royalties based on net sales under the collaboration.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["03696","IE00BYV24P56.USD","BK4588","LU0553294199.USD","SG9999004220.SGD","IE00BGHQDM52.EUR","BK1191","BK4585","BK6079","LU2346227817.USD","8A8.SI","SG9999015986.USD","LU1003077747.HKD","LU2637428348.USD","SG9999015945.SGD","LU0661504455.SGD","LU2500361329.USD","SG9999015978.USD","IE00BMCWC346.EUR","LU0545039389.USD","LU0738911758.USD","IE00BVYPNP33.GBP","00867","SG9999015952.SGD","LU2488822045.USD","LU1894683264.USD","LU0949170772.SGD","BK1593","LU1894683348.USD","IE00BVYPNQ40.USD","BK4208","CMS","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174686344","title":"CMS Repurchases 5.38 Million Shares in June, Outstanding Share Count Trimmed to 2.43 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1174686344","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174686344?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:33","pubTimestamp":1782984829,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited (CMS) filed its Monthly Return for the period ended 30 June 2026, highlighting a disciplined share-buyback programme that drove a modest contraction in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647376299","title":"China Medical System Files Board, Board Committee and Management Disclosure Roster","url":"https://stock-news.laohu8.com/highlight/detail?id=2647376299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647376299?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:38","pubTimestamp":1782733133,"startTime":"0","endTime":"0","summary":"China Medical System files board, board committee and management disclosure rosterChina Medical System set its board lineup dated June 29, 2026, led by Chairman, CEO, President Lam Kong.Executive dire","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL70GsCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","00867","IE00BYV24P56.USD","SG9999015952.SGD","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","SG9999015986.USD","SG9999004220.SGD","IE00BMCWC346.EUR","SG9999015978.USD","BK1593","IE00BVYPNP33.GBP","BK1191","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138878343","title":"CMS Appoints Li Xianliang as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1138878343","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138878343?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:36","pubTimestamp":1782732975,"startTime":"0","endTime":"0","summary":"CMS (HKEX: 00867) has announced that Mr. Li Xianliang has been appointed as an Independent Non-Executive Director of the company.The appointment is set to take effect from June 29, 2026.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","IE00BVYPNQ40.USD","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999004220.SGD","BK1191","IE00BGHQDM52.EUR","00867","SG9999015945.SGD","SG9999015978.USD","SG9999015986.USD","SG9999015952.SGD","IE00BVYPNP33.GBP","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130236598","title":"CMS repurchases 0.50 million shares for HK$5.06 million; treasury stock rises to 6.40 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1130236598","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130236598?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:23","pubTimestamp":1782300197,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited (CMS) disclosed a share repurchase of 0.50 million ordinary shares on 24 June 2026 via on-market transactions on the Hong Kong Stock Exchange. The purchase was...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645748840","title":"How NMPA Approval of First-in-Class Rabies Antibody Will Impact China Medical System (SEHK:867) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2645748840","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645748840?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:27","pubTimestamp":1782138436,"startTime":"0","endTime":"0","summary":"China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate.\nThis approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BVYPNP33.GBP","SG9999015978.USD","SG9999015986.USD","SG9999015952.SGD","ISBC","SG9999004220.SGD","IE00BVYPNQ40.USD","ARTY","LU2488822045.USD","IE00BGHQDM52.EUR","BK4211","00867","SG9999015945.SGD","BK1593","CHAT","IE00BYV24P56.USD","BK1191","AIPO","IE00BMCWC346.EUR","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645602200","title":"China Medical System Gets China Nod for Rabies Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2645602200","media":"MT Newswires","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645602200?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:51","pubTimestamp":1782132682,"startTime":"0","endTime":"0","summary":"China Medical System  obtained approval for the new drug application of Silevimig Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The product is indicated for passive immunization in adults following rabies virus exposure.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","IE00BYV24P56.USD","SG9999004220.SGD","IE00BGHQDM52.EUR","SG9999015978.USD","BK1593","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","SG9999015952.SGD","BK6079","BK1191","8A8.SI","00867","LU2488822045.USD","IE00BMCWC346.EUR","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100750850","title":"CMS Secures Chinese NDA Approval for Novel Anti-Rabies Bispecific Antibody Sileweimimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1100750850","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100750850?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:38","pubTimestamp":1782121132,"startTime":"0","endTime":"0","summary":"CMS has announced that the new drug application for its Class 1 therapeutic biologic, Sileweimimab (GR1801) Injection, has been approved by China's National Medical Products Administration. The drug...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNP33.GBP","SG9999015978.USD","BK1593","LU2488822045.USD","SG9999015986.USD","IE00BVYPNQ40.USD","SG9999004220.SGD","IPOS","IE00BYV24P56.USD","SG9999015952.SGD","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","SG9999015945.SGD","BK1191","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645822023","title":"China Medical System says China approves rabies antibody drug Silevimig Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2645822023","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645822023?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:31","pubTimestamp":1782120675,"startTime":"0","endTime":"0","summary":"China Medical System won China NMPA marketing clearance for Silevimig Injection, a Class 1 bispecific antibody for post-exposure rabies passive immunization.The group holds exclusive commercialization rights in mainland China under a 2025 deal with Chongqing Genrix Biopharmaceutical.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLNGZ4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","IE00BYV24P56.USD","IE00BVYPNP33.GBP","LU2488822045.USD","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","BK1191","SG9999015986.USD","688443","SG9999004220.SGD","BK1593","SG9999015952.SGD","SG9999015945.SGD","BK0239","00867","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645238060","title":"China Medical System - Silevimig Injection Approved by China Nmpa on 22 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645238060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645238060?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:31","pubTimestamp":1782120673,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S0A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","BK1593","SG9999015952.SGD","IE00BMCWC346.EUR","SG9999015978.USD","BK1191","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999015986.USD","IE00BYV24P56.USD","SG9999015945.SGD","00867","SG9999004220.SGD","IE00BVYPNP33.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":0.1911},{"period":"3month","weight":-0.0851},{"period":"6month","weight":-0.1091},{"period":"1year","weight":-0.0681},{"period":"ytd","weight":-0.0518}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Medical System Holdings Ltd is an investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010995},{"month":2,"riseRate":0.6,"avgChangeRate":0.034643},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.007421},{"month":4,"riseRate":0.5,"avgChangeRate":0.025609},{"month":5,"riseRate":0.4375,"avgChangeRate":-0.000081},{"month":6,"riseRate":0.625,"avgChangeRate":0.003785},{"month":7,"riseRate":0.5625,"avgChangeRate":0.002866},{"month":8,"riseRate":0.4,"avgChangeRate":0.021864},{"month":9,"riseRate":0.466667,"avgChangeRate":0.005632},{"month":10,"riseRate":0.5,"avgChangeRate":0.008421},{"month":11,"riseRate":0.5625,"avgChangeRate":0.05425},{"month":12,"riseRate":0.5625,"avgChangeRate":0.034371}],"exchange":"SEHK","name":"CMS","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CMS(00867) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CMS,00867,CMS股票,CMS股票老虎,CMS股票老虎国际,CMS行情,CMS股票行情,CMS股价,CMS股市,CMS股票价格,CMS股票交易,CMS股票购买,CMS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CMS(00867),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CMS(00867) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}